Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice

Fig. 2

The cumulative incidence of grade 2 or higher radiation pneumonitis (RP) and grade 3 or higher RP are shown. Death due to RP was regarded as a competing risk, and the curve of the competing risk is not shown. The 1-year cumulative incidences of grade 2 or higher RP and grade 3 or higher RP were 33.8% and 10.3%, respectively

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us